Directly Compressible Excipients for Orally Disintegrating Tablets **GRANFILLER-D**TM GNF-D211 GNF-D215

Product Features

- GRANFILLER-D is a co-processed excipient intended for preparing Orally Disintegrating Tablets (ODTs).
- It is designed to achieve rapid disintegration while maintaining high tablet hardness.
- Composed of four compendial grade excipients, D-Mannitol, Microcrystalline Cellulose, Carmellose and Crospovidone.
- Regulatory status: Listed in JPE2018, US-DMF filed.

 Tablet containing GRANFILLER-D disintegrates rapidly when contacting with water.

 Creamy!

Characteristics

Well-balanced tablet property between OD time and hardness

Excellent content uniformity

Compatible with various excipients

High API loading capacity


Powder Properties

	GNF-D211	GNF-D215	GNF-D211	GNF-D215		
Mean Particle Size⁺	100 µm	140 µm				
Bulk Density	0.30 g/cm ³	0.31 g/cm ³	100µm	100μm		
Tapped Density	0.44 g/cm ³	0.43 g/cm ³	A STOR			
Water Content	3.8 wt%	3.7 wt%	AND SE			
Angle of Repose	40°	39°				
Orifice Diameter	6.3 mm	4.0 mm	5 00kV 10 0mm x300 SE 2014/09/12	53400 5.00kV 9.8mm x300 SE 2016/10/06 100um		

*Measured by dry laser diffraction / light scattering particle counter.

Tablet Properties (Placebo)

Tablets using GRANFILLER-D achieve "100 N tablet hardness" and "20 seconds oral disintegration time."



Components of ODT:

GNF-D211/GNF-D215 (99.5%) + Mg Stearate (0.5%) Tablet Shape:

- 250 mg, φ 8 mm, Flat bevelled edge
- Tableting Condition :
- Rotary-press, 20 rpm
- Tablet Hardness :
- Measured by electronic hardness tester (Avg. of n=10) Disintegration Time :
- Measured by JP general test method (Avg. of n=6) Oral Disintegration Time (in vivo):
- 3 times at a time measured by 3 adults (Avg. of n=9) Oral Disintegration Time (in vitro):
 - Measured by Tricorptester (Okada Seiko Co., Ltd. Japan)


Tablet Properties (Containing API)

GRANFILLER-D enables high content of API while maintaining high tablet hardness and rapid disintegration.

30 **Disintegration Time [s]** 20 10 Composition: GNF-D211 + API + Mg Stearate (0.5% -1.5%) + LASA (1.0%) Acetaminophen: 50% Tablet Shape: 250 mg, φ8 mm, Flat-bevelled edge -Ibuprofen: 50% Tableting Condition: Rotary-press, 20 rpm Ethenzamide: 70% Tablet Hardness: Measured by electronic hardness tester (Ave. of n = 10) Disintegration Time: Measured by JP general test method (Ave. of n = 6) 0 20 40 60 80 **Tablet Hardness [N]**

Content Uniformity

Content uniformity of API turned out to be excellent for ODTs with GRANFILLER-D.



Recovery rate of Ibuprofen (IBP) in each tablet was measured at 0, 30, 60 minutes during tableting by rotary-press.

Composition:

Tableting Method:

Tableting Condition:

GNF-D211(98.5%)+IBP*(1%)+Mg Stearate (0.5%) *Mean particle size of 57µm 200 mg, φ8 mm, Flat bevelled edge Rotary-press, 30 rpm

Preparation of Various Tablets

GRANFILLER-D can be applied to various tablet shapes, such as mini-tablets and Coin-shaped tablets which show ultra rapid disintegration.

	Normal Tablet (*1)		Coin-shaped Tablet (*2)			Mini Tablet (*3)	
Tablet Weight [mg]	250			150			15
Tablet Diameter, Thickness [mm]	Ф8, 3.8 - 4.4		Φ14, 0.8			Φ2.5, 2.5	
Ethenzamide [%]	70	-	-	30	-	-	-
Acetaminophen [%]	-	50	-	-	10	-	9.8
Ascorbic Acid [%]	-	-	30	-	-	10	-
Tablet Hardness [N]	80	61	50	16	13	13	14
Disintegration Time [s]	18	23	26	5.8	5.5	6.2	2.2
Oral Disintegration Time [s]	-	-	-	5.7	6.1	3.6	2.4
Friability [%]	0.30	0.30	0.29	0.98	0.63	0.96	0.14
ponents of Tablet: *1 GNF-D211 + API + LASA (1.0%) + Mg Stearate (0.5 - 1.5%) Tableting Condition: Rotary-press, 10-20 rpm						1	

vig : *2 GNF-D211 + API + LASA (1.0%) + Mg Stearate (0.3 - 0.7%) *3 GNF-D211 (88.2%) + Acetaminophen (9.8%) + SSF (2.0%) Tablet hardness:

Measured by electronic hardness tester (Ave. of n = 10) Disintegration time: Measured by JP general test method (Ave. of n = 6)

Daicel Corporation

1-8-23, Konan, Minato-ku, Tokyo, 108-0075, Japan

TEL: +81-3-6711-8169 FAX: +81-3-6711-8168

https://daicel-excipients.com/ daicel-excipients@jp.daicel.com

GRANFILLER-D was jointly developed by DAICEL Group and NICHIRIN CHEMICAL INDUSTRIES, LTD.

Disclaimer Daicel has paid special attention to ensure that the information included on this document will be updated and accurate. However, Daicel does not guarantee or accept any responsibility for the appropriateness and accuracy of the content of this document. Additionally, please approve of the fact that the content of this document may be changed, or suspended, or the operation thereof ceased, without prior notice. Regardless of reason, Daicel does not assume responsibility for the operation thereof ceased without prior notice. of this document. Additionally, please approve of the fact that the content of th for any damages arising from changes of the data on this document. (01/2019)

